GMAB Stock Forecast & Price Target

Genmab is increasingly viewed as a diversified oncology platform rather than a royalty-dependent biotech, with profitable operations and a growing mix of wholly owned and profit-shared assets that can offset the expected decline in Darzalex and the broader royalty base later in the decade. Its positive Phase 3 readouts for petosemtamab and Rina-S materially de-risk two potential blockbuster franchises, while Epkinly adds another high-value anchor, and the model now implies substantial future revenue potential from these three assets alone. With multiple upcoming data readouts, label-expansion opportunities, and potential 2027 approvals across several programs, the company’s pipeline breadth and clinical momentum strengthen confidence in durable long-term value creation.

Genmab is facing a negative fundamental setup because its growth depends heavily on a concentrated portfolio led by Darzalex, while several other products remain exposed to lower-than-expected sales, partnership dependence, and execution risk across commercialization and supply chains. The company also faces meaningful R&D, regulatory, legal, and clinical setbacks, alongside the possibility that new competitors could erode market share in key oncology indications and weaken the economics of its antibody platform. Additional pressure comes from financing risk tied to the Merus acquisition and associated debt, which may strain liquidity and amplify broader macroeconomic, geopolitical, and intellectual property risks.